The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Probably because, if precision works, it’s going to be monumentally life changing for those invested and those being treated.
Investing now comes with risk. Investing at £30 SP has less risk.
It’s up to you.
ROTFLMAO….:-)) means Rolling On The Floor Laughing My Ass Off.
I never knew
Did the cretin just say this?
“ If they believe what they type, whats the point of staying in?”
ROTFLMAO….:-))
Ps…He’ll now use his other logins to this removed….
Because as the odds of it working improve at each release of positive data the share price will increase to reflect the chances of success. It’s pretty much how all stocks have worked forever. Dumbass.
AS was pretty pleased with result of first patient at 90% of standard dose. Was unable to say why but probably an immediately available measure such as systemic levels of dox. Great but not sure grounds for doing cartwheels.
US has approved trial - majority of data was preclinical so effectively same data has used for UK approval. Again great - third party assessment that it holds potential by two respected bodies. Not sure if one patient data really influenced them but hey if it makes people happy.....
More interesting is the study presumably continues and is now in stages where doses exceed standard. Otherwise something significant (in RNS) would have stopped / paused study. I think that is fairly exciting. Almost a no news is excellent news. Timing of announcing second project is intriguing and I like the commitment and direction.
Continue to hold based on clinical trial output required before any other action. If this works there are a lot here who will see significant changes to their own situation - like the fact that PIs with balls and prepared to risk can change their own finances so significantly.
Lee, in essence, its not going to be a rosy investor meeting without some developments.
SP having had a hammering, LFT off the market, no further update for AVA6K... only candidate selected for 3996.
Investors will be wanting a good discount to get in now, however, by then we could have LFT back on market, Update to AVA6K and seeking further investors at that point would be an easier sell.. assuming that the SP would also be recovering in the right direction, could be excellent timing for him...
Assuming he has worked out the roadmap of news leading up to the investor meeting, not just signing up blindly and trying to work it out closer to the time should developments not occur.
Historically, we have seen investor meet Company meetings (Except 1 i think) where he hasnt had anything new to say, and generally RNS just prior to allow him to give details on such new info.
Interesting interpretation of what 1a means and not aligned with my own thinking. If the data gathered indicates that the dox has been largely contained within the tumour and that the rest of the body has not suffered the usual toxic effects, which I know all too well from family illness, then Precision works. Dox works so no question mark there. The only question then becomes how much dox can you/ should you load into the tumour. So in my mind there is a big jump in the share price after successful phase 1a and lots of i terest from big pharma. Perhaps Ophidian, or others, can set me right if Im off at a tangent.
Alistair Smith would be extremely foolish to release such a positive RNS about 3996 if the early data on 6000 wasn't anything but positive, It would cost him his job imo.
I've read that that RNS several times now and it absolutely reads as everything is on track. Added with IND approval which would have included early human data in the application, I'm very confident about the progress of AVA6000.
I also don't see Avacta holding investor roadshows without an update on 6000 1st, we get news on that front in the next 7 working days imo.
"Perhaps I'm off my rocker!"
Not at all, its all written in the stars, they are aligning!
Strange situation isnt it. If I'd had cash on the side I would have bought by now! We know there is no bad news, we know the last thing stated by AS was "very pleased" we know 3 days of meet and great planned, we know we have a group of world class oncologists standing with Avacta, we know the US trial was accepted, we know the next candidate Precision Drug has been selected. What baffles me is how anyone can think an update could happen saying anything but AVA 6000 phase 1a was a success. Perhaps I'm off my rocker!
Point
Similar risk profile
Neutronic you are right but its getting fairly close - topped up at 1.87 and then sold for slight profit. My 60p top up is looking more threatened hence now waiting.
Early stage pharma stocks are volatile and you haven't made a profit or a loss until you sell. Problem is its either really fantastic or really crap when news hits. I'm guessing the LTH here have a balls of steel since most could have been on a free ride by now.
My view - dox and velcade proven efficacy. Preclinical looks promising (noone approves clinical trial if drug kills all the mice). I wouldn't be here if I wasn't positive about opportunity but I find it easier to accept its a risk rather than looking for something to latch onto in tea leaves that are not there.
Given we must be all of a similar mind to be here I'd be interested to know what other pharma stocks people are buying and how risk reward compares.
I’m no disagreeing with you, I just take a different experience from the journey and on balance of news, interpreting a different outcome, a very good one. You and I will be very happy, as will we all. Onwards and upwards.
You may be right Ndn71 and I’m sure your scenario has crossed minds but, on the other hand, should one be holding the most compelling and ground breaking data, one would sensibly cross check every detail and consider how it should be divulged and then plot a controlled release which isn’t then open for rebuttal by people with a contrarian agenda. Who knows, but certainly I don’t think either you nor I do for now.
I take a positive view on it, otherwise I wouldn’t have got involved in the first place. Happy to let this be done properly and for the Company to take the advice of experts on how to release the news of real hope for what was a previously a destructive treatment.
"Ha ha "meant nothing in particular" you are kidding right! The writing is on the wall in letters 6ft high is all! Problem is the story simply sounds too good to be true, the reality is that it is not. Life changing opportunity for those with cash to invest in my opinion. Wish I had cash to spare at this point but sadly don't.
RD, also believe lots of people are also underwater massively even after averaging down.
Your in a good spot, most probably not.
Market sentiment dominated by people who like facts rather than made up stuff by self appointed experts. If I hadn't already allocated as much id be buying - looking at the current situation and current SP Avacta represents excellent balance between risk and return even when taking into account the unknowns. I've cash on side line awaiting update - still in profit but jeez its been a ride. Suspect lots of people have same plan.
Can't be easy for you Kong, what with all that hat eating. Could be something to do with sentiment? Maybe the Yanks will turn up again this afternoon?
I think the market is looking for more detail on Ava6000 results (rather than inference from an announcement of an associated drug program) to get real buying going, and of course resolution of the Affidx saga! Both should be updated in next 2 weeks, imho.
After the news yesterday, I’m really struggling to understand the share price
Problem is that the trial data remains confidential whilst ongoing. I think the most we are likely to get is that it is on course or delayed. He won't want to give a running commentary on that but we will have to have some sort of update before his road trip. The comment he made about updating market on second cohort is confusing the issue - either it has started or has been delayed. If there was a problem with precision (mice are different to humans) then I don't think the RNs from yesterday would have been made. Dangerous but can we assume therefore all is good with ava006.
I'm hoping that we also get a ava004 update - been on the back burner for along time. Perhaps it will be a partner but cannot bang on about affirmers and then ignore their Tx potential. Probably a resources issue but would be good to see some progress.
Partnerships will be progressing albeit slowly. Update on this would also be good. Expect the roadshow is being put together with knowledge that these questions will be asked.
:0)))
pedrolancaster
Posts: 1,284
Price: 79.50
Strong Buy
"There were two bits of good news yesterday oh ye of short memory."
Have you already forgotten yesterday's update was for AVA3996, not AVA6000 ?
Have you had Covid in the past 6-9 months oh ye of short memory. ?
Fair point ;)
pedrolancaster
https://uk.news.yahoo.com/mild-covid-infection-degrades-memory-182723134.html